Report overview
Retinal Vasculitis is a type of inflammation of the blood vessel in the ocular region get inflamed because of autoimmune disorder like inflammatory disorder, infective and neoplastic disorder. These changes can restrict the blood flow, resulting in organ and tissue damage. This type of disorder occurs in the geriatric population. Corticosteroid and Immunosuppressant drugs are used as the treatment of Retinal Vasculitis. Other retinal infections also boost the Retinal Vasculitis treatment market. Conventional and biological immunosuppressants are in demand for treating Retinal Vasculitis. Manufacturers are plays important role in the research and development of new drugs for the treatment of Retinal Vasculitis.
This report contains market size and forecasts of Retinal Vasculitis Treatment in global, including the following market information:
Global Retinal Vasculitis Treatment Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global Retinal Vasculitis Treatment Market Sales, 2018-2023, 2023-2030, (K Units)
Global top five Retinal Vasculitis Treatment companies in 2022 (%)
The global Retinal Vasculitis Treatment market was valued at million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Immunosuppressive Drug Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Retinal Vasculitis Treatment include Celgene Corporation, Merck & Co, Novartis AG, F. Hoffmann-La Roche, GlaxoSmithKline plc, Bristol-Myers Squibb Company, RNL BIO Co., Ltd., Teijin Pharma Limited and Anthera Pharmaceuticals, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Retinal Vasculitis Treatment manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Retinal Vasculitis Treatment Market, by Type, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Retinal Vasculitis Treatment Market Segment Percentages, by Type, 2022 (%)
Immunosuppressive Drug
corticosteroid Drug
Global Retinal Vasculitis Treatment Market, by Application, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Retinal Vasculitis Treatment Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Others
Global Retinal Vasculitis Treatment Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Retinal Vasculitis Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Retinal Vasculitis Treatment revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Retinal Vasculitis Treatment revenues share in global market, 2022 (%)
Key companies Retinal Vasculitis Treatment sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Retinal Vasculitis Treatment sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Celgene Corporation
Merck & Co
Novartis AG
F. Hoffmann-La Roche
GlaxoSmithKline plc
Bristol-Myers Squibb Company
RNL BIO Co., Ltd.
Teijin Pharma Limited
Anthera Pharmaceuticals
Human Genome Sciences, Inc.
Novo Nordisk A/S
Eli Lilly and Company
